The Wadsworth Center’s Dr. Kurunthachalam Kannan Honored as Outstanding Researcher at University at Albany Research and Education Week

Dr. Kurunthachalam Kannan, Deputy Director of the Division of Environmental Health Sciences at the Wadsworth Center and Professor at the University at Albany, was recognized as an Outstanding Researcher during the university’s annual Research and Education (R&E) Week Awards Ceremony held on Friday, October 31. This year’s R&E Week theme, “Celebrating Research from Innovation to Impact,” highlighted the transformative role of research in improving communities and advancing public health.

Dr. Rajendra Agrawal Presents at the “Mechanisms and Milestones in Translation” Symposium

Dr. Rajendra Agrawal of the Wadsworth Center was invited to speak at the Ehrenberg–Liljas Symposium on Mechanisms and Milestones in Translation, held at Uppsala University, Sweden, on October 27–28, 2025. The meeting honored the pioneering contributions of Professors Måns Ehrenberg and Anders Liljas, both distinguished ribosome biologists and former members of the Nobel Prize Committee. 

Wadsworth Center Researcher Abhishek Jain, PhD Recognized for Contributions to the Field of Bioanalysis Made During Time at Yale, Uppsala and Nanyang Technological Universities

Dr. Abhishek Jain is a newly recruited investigator in the Wadsworth Center’s Division of Environmental Health Sciences, and has been selected to receive The Bioanalysis Rising Star award recognizing the most promising early-career scientists in the field of bioanalysis. The vision of this award is to promote the work of highly talented researchers, offering a springboard to help establish themselves in the exciting world of bioanalysis. This award recognizes Dr. Jain’s overall contributions to the field of bioanalysis over the past 10 years.  

Wadsworth Center Co-Hosts Wastewater Surveillance Summit

The Wadsworth Center, in collaboration with the Center for Environmental Health and Syracuse University, hosted a Wastewater Surveillance Summit on October 23. The event brought together experts from public health, academia, and research organizations to discuss innovations, share experiences, and explore future directions in wastewater-based surveillance. 

Wadsworth Center Staff to Serve on the Association of Public Health Laboratories’ Overdose Biosurveillance Task Force

Dr. Kurunthachalam Kannan from the Division of Environmental Health Sciences (DEHS) at the Wadsworth Center, has been invited to serve on the Overdose Biosurveillance Task Force (OBTF), an advisory group charged by the Association of Public Health Laboratories (APHL) Board of Directors to provide subject matter expertise and input into the creation, dissemination, and promotion of resources for public health laboratories developing and conducting overdose biosurveillance programs in response to the evolving overdose epidemic. 

The Wadsworth Center Develops and Validates a New Method for the Analysis of Drugs in Urine from Overdose Patients

Fatal drug poisoning (“overdose”) is a growing public health crisis in the United States. According to the United States National Vital Statistics System, 105,007 drug overdose deaths occurred in 2023. Whereas opioids (including prescription opioids, heroin, fentanyl and analogs) were the leading cause of overdose deaths, the pharmacological composition of drugs has evolved into a “polysubstance death” crisis.  

The Wadsworth Center’s Dr. Denise Kay Discusses Complexities of Cystic Fibrosis Genetic Analysis at the North American Cystic Fibrosis Conference

Dr. Denise Kay, Director of the New York State Newborn Screening Program at the Wadsworth Center, was invited to present at the 2025 North American Cystic Fibrosis Conference, held October 22–25 in Seattle, Washington.

Wadsworth Center’s Mycobacteriology Laboratory Provides Critical Testing for Texas Drug-Resistant Tuberculosis Case

The Wadsworth Center’s Mycobacteriology Laboratory was contacted by the Texas Department of State Health Services to perform drug susceptibility testing for a transplant recipient previously treated for pre-extensively drug-resistant (XDR) tuberculosis beginning in 2022. After nine months of therapy, the patient was initially deemed cured following a treatment regimen consisting of bedaquiline, pretomanid, and linezolid (BPaL)—currently the standard for managing multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).